|
2025 Journal Article Evaluating clinician sustainment of a Mediterranean‐style dietary pattern approach in routine care for coronary heart disease and type 2 diabetes utilizing Normalization MeAsure Development (NoMAD) instrumentMayr, Hannah L., Murray, Eryn, Maher, Patrick, Hayes, Lisa, Wang, William Y. S., Kelly, Jaimon T., Palmer, Michelle, Martin, Andrew and Hickman, Ingrid J. (2025). Evaluating clinician sustainment of a Mediterranean‐style dietary pattern approach in routine care for coronary heart disease and type 2 diabetes utilizing Normalization MeAsure Development (NoMAD) instrument. Nutrition in Clinical Practice, 40 (6) ncp.70055, 1552-1569. doi: 10.1002/ncp.70055 |
|
2025 Journal Article Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trialsMartin, Andrew J., Soon, Yu Yang, Sjoquist, Katrin Marie, Pavlakis, Nick, Goldstein, David, Shitara, Kohei and Simes, John R. (2025). Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials. Gastric Cancer. doi: 10.1007/s10120-025-01670-2 |
|
2025 Journal Article Oncologist and General Practitioner Perspectives of Shared Care for Colorectal Cancer Survivors: A Qualitative StudyLisy, Karolina, Tieu, Matthew, Gore, Claire, Schofield, Penelope, Chan, Raymond J., Emery, Jon, Martin, Andrew, De Abreu Lourenco, Richard and Jefford, Michael (2025). Oncologist and General Practitioner Perspectives of Shared Care for Colorectal Cancer Survivors: A Qualitative Study. Psycho-Oncology, 34 (7) e70223, 7. doi: 10.1002/pon.70223 |
|
2025 Journal Article INTEGRATE pooled phase II/III results are robust to post-progression switching and winner’s curseSoon, Yu Yang, Sjoquist, Katrin, Marschner, Ian C, Schou, I Manjula, Pavlakis, Nick, Goldstein, David, Shitara, Kohei, Stockler, Martin R, Simes, John and Martin, Andrew J (2025). INTEGRATE pooled phase II/III results are robust to post-progression switching and winner’s curse. JNCI Cancer Spectrum, 9 (4) pkaf053. doi: 10.1093/jncics/pkaf053 |
|
2025 Journal Article Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialKwan, Edmond M., Ng, Sarah W. S., Tolmeijer, Sofie H., Emmett, Louise, Sandhu, Shahneen, Buteau, James P., Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze-Ting, Scott, Andrew M., Martin, Andrew J., Stockler, Martin R., Donnellan, Grainne, Annala, Matti, Herberts, Cameron, Davis, Ian D., Hofman, Michael S., Azad, Arun A., Wyatt, Alexander W., Akhurst, Tim, Alipour, Ramin, Bailey, Dale L., Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Chua, Wei, Crumbaker, Megan ... Zhang, Alison Y. (2025). Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nature Medicine, 2025 (8), 1-15. doi: 10.1038/s41591-025-03704-9 |
|
2025 Journal Article Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304)Lin, H.-M., Scheinberg, T., Portman, N., Kim, R.M.N., Mellor, R., Hunyh, K., Faulkner, A.N., Mellett, N.A., Davis, I.D., Martin, A., Sullivan, D., Joshua, A., McJannett, M., Subhash, V., Yip, S., Azad, A.A., Marschner, I.C., North, S.A., McDermott, R.S., Chi, K.N., Stockler, M.R., Sweeney, C.J., Meikle, P.J. and Horvath, L.G. (2025). Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304). Annals of Oncology, 36 (9), 1068-1077. doi: 10.1016/j.annonc.2025.05.529 |
|
2025 Journal Article Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M, Sandhu, Shahneen, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Kumar, Aravind S Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick ... Bills, Madison (2025). Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (3), 291-299. doi: 10.1016/s1470-2045(25)00009-9 |
|
2025 Journal Article Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)Conduit, Ciara, Inderjeeth, Andrisha-Jade, Allen, Raymond, Martin, Andrew J., Parulekar, Wendy, Mulroe, Eibhlin, McJannett, Margaret, Zielinski, Robert R., Thomson, Alastair, Tan, Thean Hsiang, Sandhu, Shahneen K., Reaume, M. Neil, Pook, David W., North, Scott A., Marx, Gavin M., Joshua, Anthony, Horvath, Lisa, McDermott, Ray, Chowdhury, Simon, Chi, Kim N., Zhang, Alison Y., Stockler, Martin R., Davis, Ian D., Sweeney, Christopher J. and on behalf of ANZUP Cancer Trials Group (2025). Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304). Future Oncology, 21 (6), 627-636. doi: 10.1080/14796694.2024.2440277 |
|
2025 Journal Article Balancing precision and affordability in assessing infant development in large-scale mortality trials: Secondary analysis of a randomised controlled trialRobledo, Kristy P., Rieger, Ingrid, Finlayson, Sarah, Tarnow-Mordi, William and Martin, Andrew J. (2025). Balancing precision and affordability in assessing infant development in large-scale mortality trials: Secondary analysis of a randomised controlled trial. Archives of Disease in Childhood: Fetal and Neonatal Edition, 110 (4), F409-F414. doi: 10.1136/archdischild-2024-327762 |
|
2025 Journal Article Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Sandhu, Shahneen, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ayati, Narjess, Niu, Claire, Hofman, Michael S, Martin, Andrew James, Thomas, Hayley, Davis, Ian D and Stockler, Martin R (2025). Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (9), 1168-1177. doi: 10.1016/S1470-2045(25)00339-0 |
|
2024 Journal Article INTEGRATE IIa Phase III Study: Regorafenib for refractory advanced gastric cancerPavlakis, Nick, Shitara, Kohei, Sjoquist, Katrin, Martin, Andrew, Jaworski, Anthony, Tebbutt, Niall, Bang, Yung-Jue, Alcindor, Thierry, O'Callaghan, Chris, Strickland, Andrew, Rha, Sun Young, Lee, Keun-Wook, Kim, Jin-Soo, Bai, Li-Yuan, Hara, Hiroki, Oh, Do-Youn, Yip, Sonia, Zalcberg, John, Price, Tim, Simes, John and Goldstein, David (2024). INTEGRATE IIa Phase III Study: Regorafenib for refractory advanced gastric cancer. Journal of Clinical Oncology, 43 (4), 453-463. doi: 10.1200/jco.24.00055 |
|
2024 Journal Article Lu-177 PSMA vs comparator treatments and survival in metastatic castration-resistant prostate cancerSoon, Yu Yang, Marschner, Ian C., Schou, Manjula, Hofman, Michael S., Emmett, Louise, Davis, Ian D., Stockler, Martin R. and Martin, Andrew J. (2024). Lu-177 PSMA vs comparator treatments and survival in metastatic castration-resistant prostate cancer. JAMA Network Open, 7 (9) e2433863, 1-13. doi: 10.1001/jamanetworkopen.2024.33863 |
|
2024 Journal Article Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritanceSharifi, Nima, Diaz, Robert, Lin, Hui-Ming, Roberts, Evan, Horvath, Lisa G., Martin, Andrew, Stockler, Martin R., Yip, Sonia, Subhash, Vinod V., Portman, Neil, Davis, Ian D. and Sweeney, Christopher J. (2024). Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance. Journal of Clinical Investigation, 134 (18) e183583, 1-9. doi: 10.1172/jci183583 |
|
2024 Journal Article Challenges of estimating treatment effects after a positive interim analysisSoon, Yu Yang, Marschner, Ian C., Schou, Manjula, Sweeney, Christopher J., Davis, Ian D., Stockler, Martin R. and Martin, Andrew J. (2024). Challenges of estimating treatment effects after a positive interim analysis. European Journal of Cancer, 209 114230, 114230. doi: 10.1016/j.ejca.2024.114230 |
|
2024 Journal Article Correction to: Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals (Supportive Care in Cancer, (2022), 30, 9, (7763-7772), 10.1007/s00520-022-07167-3)Nahm, Sharon H., Stockler, Martin R., Martin, Andrew J., Grimison, Peter, Fox, Peter, Zielinski, Rob, Hawson, Geoffrey AT., Tattersall, Martin HN. and Kiely, Belinda E. (2024). Correction to: Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals (Supportive Care in Cancer, (2022), 30, 9, (7763-7772), 10.1007/s00520-022-07167-3). Supportive Care in Cancer, 32 (6) 386. doi: 10.1007/s00520-024-08597-x |
|
2024 Journal Article [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Gedye, Craig, Rutherford, Natalie K., Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P., Voskoboynik, Mark, Redfern, Andrew D., Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Davis, Ian D. (2024). [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. The Lancet Oncology, 25 (5), 563-571. doi: 10.1016/s1470-2045(24)00135-9 |
|
2024 Journal Article Validation of prognostic and predictive models for therapeutic response in patients treated with [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a post hoc analysis from a randomised, open-label, phase 2 trialGafita, Andrei, Martin, Andrew J., Emmett, Louise, Eiber, Matthias, Iravani, Amir, Fendler, Wolfgang P., Buteau, James, Sandhu, Shahneen, Azad, Arun A, Herrmann, Ken, Stockler, Martin R., Davis, Ian D. and Hofman, Michael S. (2024). Validation of prognostic and predictive models for therapeutic response in patients treated with [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a post hoc analysis from a randomised, open-label, phase 2 trial. European Urology Oncology, 8 (1), 21-28. doi: 10.1016/j.euo.2024.03.009 |
|
2024 Journal Article Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation frameworkCho, Doah, Lord, Sarah J., Ward, Robyn, IJzerman, Maarten, Mitchell, Andrew, Thomas, David M., Cheyne, Saskia, Martin, Andrew, Morton, Rachael L., Simes, John and Lee, Chee Khoon (2024). Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework. Therapeutic Advances in Medical Oncology, 16, 1-20. doi: 10.1177/17588359241273062 |
|
2024 Journal Article Colorectal cancer survivors' experiences and views of shared and telehealth models of survivorship care: a qualitative studyGore, Claire, Lisy, Karolina, O’Callaghan, Clare, Wood, Colin, Emery, Jon, Martin, Andrew, De Abreu Lourenco, Richard, Schofield, Penelope and Jefford, Michael (2024). Colorectal cancer survivors' experiences and views of shared and telehealth models of survivorship care: a qualitative study. Psycho-Oncology, 33 (1) e6265. doi: 10.1002/pon.6265 |
|
2024 Journal Article Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialHofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R., Williams, Scott G. ... Yip, Sonia (2024). Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. The Lancet Oncology, 25 (1), 99-107. doi: 10.1016/s1470-2045(23)00529-6 |
